Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-01-02 Beta blockers
Propranolol – see section 02.04
| Propranolol |
|
Formulary
|
Tablets 10mg, 40mg, 80mg Anxiety with symptoms such as palpitation, sweating and tremor. Note: significant risks when taken in overdose. Potential for rapid deterioration before medical assistance is received. |
 Prescribing Alert - Propranolol SMU-21-Propranolol-in-anxiety-Final |
|
Links
- LSCMMG: ADHD combined adult and child shared care guideline
- LSCMMG: Opioid reduction: best interests opioid reduction position statement
- LSCMMG: Opioid treatment: patient-prescriber opioid treatment agreement
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- MHRA Drug Safety Update April 2016: Meprobamate: licence to be cancelled
- MHRA Drug Safety Update April 2022: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA Drug Safety Update Feb 2021: Pregabalin (Lyrica): reports of severe respiratory depression
- MHRA: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
- MHRA: Changes to drug driving law
- MHRA: Drugs and driving: blood concentration limits to be set for certain controlled drugs in a new legal offence
- MHRA: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April
- MHRA: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA: Pregabalin (Lyrica): reports of severe respiratory depression
- NICE CG113: Generalised anxiety disorder and panic disorder in adults: management
- NICE NG163: COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community
- NICE NG215: Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults
- Prescribing Alert - Propranolol
- SMU-21-Propranolol-in-anxiety-Final